Hematology

PSI is a leading full-service CRO with 800+ staff in Europe (Eastern, Central, Western), the USA and Latin America.

PSI is known and respected for consistently securing fast patient enrollment into clinical trials of all sizes and levels of complexity, across a broad range of indications.

PSI has successfully performed Phase II/III studies in the following hematology indications:

Chronic lymphocytic leukemia
Acute myeloid leukemia
Secondary AML
Multiple myeloma
Idiopathic thrombocytopenic purpura
Thrombocytopenia
Hemophilia A
Non-Hodgkin's Lymphoma

PSI has performed feasibility studies in the following indications:

Myelodysplastic Syndrome (MDS)
Hodgkin's Lymphoma

PSI has developed a database of 300+ sites treating patients with hematologic disorders, grouped by indication, as listed below:

Hematology Indication	# Sites
Non-Hodgkin's Lymphoma	80
Chronic lymphocytic leukemia	60
Acute and secondary myeloid leukemia	120
Multiple myeloma	40
Idiopathic thrombocytopenic purpura	10
Thrombocythemia	10
Hemophilia A	30
	350

PSI employs physicians as full-time monitors and project managers, most of whom are board certified specialists, including hematologists.